Tenuous economic conditions have prompted Targeted Genetics Corp. to reduce expenses by eliminating jobs and placing certain projects on the backburner, the company's president and CEO said. (BioWorld Today)

Tenuous economic conditions have prompted Targeted Genetics Corp. to reduce expenses by eliminating jobs and placing certain projects on the backburner, the company's president and CEO said. (BioWorld Today)

BETHESDA, Md. - An FDA panel of experts unanimously recommended approval of Gilead Sciences Inc.'s once-daily tablet, adefovir dipivoxil, for chronic hepatitis B. (BioWorld Today)

BETHESDA, Md. - An FDA panel of experts unanimously recommended approval of Gilead Sciences Inc.'s once-daily tablet, adefovir dipivoxil, for chronic hepatitis B. (BioWorld Today)

Gilead Sciences Inc., seeking its second significant product approval in a year, is going before an FDA advisory panel today that is expected to issue a recommendation on Gilead's new drug application for adefovir dipivoxil, a once-daily oral treatment for hepatitis B. (BioWorld Today)

Gilead Sciences Inc., seeking its second significant product approval in a year, is going before an FDA advisory panel today that is expected to issue a recommendation on Gilead's new drug application for adefovir dipivoxil, a once-daily oral treatment for hepatitis B. (BioWorld Today)

Genentech Inc. and XOMA Ltd. said preliminary data from a long-term study of their psoriasis drug indicates that most patients who complete one year of therapy maintain a 50 percent or greater improvement in their condition. (Bioworld Today)

Genentech Inc. and XOMA Ltd. said preliminary data from a long-term study of their psoriasis drug indicates that most patients who complete one year of therapy maintain a 50 percent or greater improvement in their condition. (Bioworld Today)